| Mary Ruth Lopez, Md Pllc | |
|
233 Warm Springs Ave Martinsburg WV 25404-3825 | |
| (304) 262-8686 | |
| (240) 485-0916 |
| Full Name | Mary Ruth Lopez, Md Pllc |
|---|---|
| Speciality | Family Medicine |
| Location | 233 Warm Springs Ave, Martinsburg, West Virginia |
| Authorized Official Name and Position | Mary Ruth M Lopez (PHYSICIAN) |
| Authorized Official Contact | 3042628686 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mary Ruth Lopez, Md Pllc 233 Warm Springs Ave Martinsburg WV 25404-3825 Ph: (304) 262-8686 | Mary Ruth Lopez, Md Pllc 233 Warm Springs Ave Martinsburg WV 25404-3825 Ph: (304) 262-8686 |
| NPI Number | 1194112524 |
|---|---|
| Provider Enumeration Date | 04/23/2015 |
| Last Update Date | 04/23/2015 |
| Medicare PECOS PAC ID | 2961722293 |
|---|---|
| Medicare Enrollment ID | O20150527002387 |
News Archive
The National Institutes of Health has awarded $10.24 million to Fred Hutchinson Cancer Research Center to lead a five-year study that aims to understand and prevent breast cancer disparities in Hispanic women.
Studies examining the effects of the use of postmenopausal hormone therapy on coronary heart disease (CHD) have yielded mixed results, depending on the type of study conducted. There may be a number of reasons for the differences, including the timing of initiation of hormone therapy, according to background information in the article.
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
The earlier in life children reach their lowest body mass index (BMI) signals potential heart disease risk factors and may become evident as early as age 7, researchers reported at the American Heart Association's Scientific Sessions 2007.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194112524 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 22265 (West Virginia) | Primary |
| Provider Name | Mary Ruth M Lopez |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154371912 PECOS PAC ID: 6800895475 Enrollment ID: I20061208000001 |
News Archive
The National Institutes of Health has awarded $10.24 million to Fred Hutchinson Cancer Research Center to lead a five-year study that aims to understand and prevent breast cancer disparities in Hispanic women.
Studies examining the effects of the use of postmenopausal hormone therapy on coronary heart disease (CHD) have yielded mixed results, depending on the type of study conducted. There may be a number of reasons for the differences, including the timing of initiation of hormone therapy, according to background information in the article.
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
The earlier in life children reach their lowest body mass index (BMI) signals potential heart disease risk factors and may become evident as early as age 7, researchers reported at the American Heart Association's Scientific Sessions 2007.
› Verified 7 days ago
News Archive
The National Institutes of Health has awarded $10.24 million to Fred Hutchinson Cancer Research Center to lead a five-year study that aims to understand and prevent breast cancer disparities in Hispanic women.
Studies examining the effects of the use of postmenopausal hormone therapy on coronary heart disease (CHD) have yielded mixed results, depending on the type of study conducted. There may be a number of reasons for the differences, including the timing of initiation of hormone therapy, according to background information in the article.
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.
The earlier in life children reach their lowest body mass index (BMI) signals potential heart disease risk factors and may become evident as early as age 7, researchers reported at the American Heart Association's Scientific Sessions 2007.
› Verified 7 days ago
West Virginia University Medical Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2010 Doctor Oates Dr Ste 103, Martinsburg, WV 25401 Phone: 304-596-5142 Fax: 304-596-5143 | |
Family Medicine Of Martinsburg, Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 651 Foxcroft Ave, Suite 110, Martinsburg, WV 25401 Phone: 304-264-3660 Fax: 304-264-3665 | |
Valley Health Berkeley Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 101 Marcley Dr, Martinsburg, WV 25401 Phone: 304-263-8911 | |
Shenandoah Valley Medical System, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 99 Tavern Rd, Martinsburg, WV 25401 Phone: 304-263-4999 | |
Panhandle Medicine Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 35 Aikens Ctr, Martinsburg, WV 25404 Phone: 304-264-2290 Fax: 304-264-2295 | |
Wexford Health Solutions Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 94 Grapevine Rd, Martinsburg, WV 25405 Phone: 630-730-0302 | |
Valley Health Family Medicine - Briarwood Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1004 Sushruta Dr, Suite D, Martinsburg, WV 25401 Phone: 304-262-2538 Fax: 304-262-2583 |